Current Opinion in Organ Transplantation was launched in 1996. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of organ transplantation is divided into 18 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Manuel A. Pascual
Manuel Pascual graduated and received his MD in 1986 at the University of Geneva, Switzerland. He undertook his residency in internal medicine at the University Hospital of Geneva, where he subsequently worked as a postdoctoral research fellow in immunonephrology. From 1993 to 2002, Dr Pascual worked in nephrology and transplantation at the Massachusetts General Hospital in Boston, USA. After completing a renal fellowship (1993–1996), he became Instructor in Medicine. In 2000, he was promoted to Assistant Professor of Medicine at Harvard Medical School, USA.
In 2003, he returned to Switzerland as Chief of the newly established Transplantation Center at the University Hospital of Lausanne (CHUV) and he became Full Professor of the Faculty of Biology and Medicine at the University of Lausanne, Switzerland. Since 2004, he has also been the Medical Director of the Centre Universitaire Romand de Transplantation, Switzerland (Lausanne-Geneva Transplant Network).
Dr Pascual's major clinical and scientific interests have been in the field of nephrology, immunology and kidney transplantation, including the humoral and cellular mechanisms of allograft rejection, the prevention and treatment of chronic allograft nephropathy and viral infections (cytomegalovirus, hepatitis C) in transplant recipients. He is the past recipient of a Clinical Science Award of the American Society of Transplantation, and is author or co-author of more than 200 publications. He has served as President of the Swiss Transplantation Society (2008–2010) and he is a member of several international societies. Currently, he is also a member of the executive office of the Swiss Transplant Cohort Study (STCS) and of the Scientific Board for Highly Specialized Medicine in Switzerland.
After completing his medical degree at Georgetown University School of Medicine, USA, Dr Dhanireddy went on to train in general surgery at Georgetown. During his surgical training, he spent 3 years with Dr Allan Kirk at the National Institutes of Health, USA. His research focus was transplantation tolerance. Specifically, Dr Dhanireddy examined the role of donor specific transfusion and costimulation blockade in a non-human primate renal allograft model. Subsequent small animal and bench mechanistic studies added to the overall understanding of donor cell induced hyporesponsiveness.
Dr Dhanireddy completed his multiorgan transplant and hepatopancreaticobiliary surgery training with Dr Ronald W Busuttil at the University of California Los Angeles, USA. He developed a keen clinical interest in liver transplantation and liver resection for hepatocellular carcinoma. Subsequently, Dr Dhanireddy joined the faculty of the Keck School of Medicine of the University of Southern California, USA. His current practice consists of abdominal transplantation and HPB surgery. He is the Director of Pancreas Transplantation and the Chief of Hepatobiliary Surgery at Los Angeles County and University of Southern California.
Dr Dhanireddy has written multiple peer reviewed manuscripts, review articles and book chapters in the fields of transplantation tolerance and surgery. He is an active member of the American Society of Transplantation, the International Liver Transplant Society and the American Society of Transplant Surgeons.
Linda S. Sher
Dr Sher is Associate Professor of Clinical Surgery and Director of Clinical Research in the Division of Hepatobiliary Surgery and Abdominal Organ Transplantation at Keck School of Medicine, University of Southern California (USC), USA. After completing her medical school education and surgical residency at Mount Sinai School of Medicine in New York, USA, Dr Sher undertook her fellowship training in liver and kidney transplantation at the University of Pittsburgh, USA. After completing her fellowship in 1988, Dr Sher was involved in the establishment of two liver transplant programs in Los Angeles prior to joining the USC program in 2001. Dr Sher has participated in and overseen over 50 research projects and is currently very active in the development of the clinical and basic science research components of the USC Abdominal Organ Transplantation Program. She has numerous publications on immunosuppression, chronic rejection, disease recurrence, infection, prophylaxis and hepatobiliary surgery.
Dr Sher is one of the original editors of Current Opinion in Organ Transplantation and has endeavored over the years to provide the reader with an up to date overview of the entire field of organ transplantation.
Dr Marc Penn is a cardiologist and Director of Research at Summa Cardiovascular Institute in Akron, Ohio, USA and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University, USA, where he leads the Skirball Laboratory for Cardiovascular Cellular Therapeutics. Dr Penn completed his studies at Case Western Reserve University, USA, completing a Ph.D. in biomedical engineering in 1989 and doctor of medicine in 1994. He completed internal medicine training at University Hospitals of Cleveland, USA, and cardiovascular medicine fellowship at Cleveland Clinic, USA. During his training he received numerous awards including the 1999 American Heart Association Irvine H. Page Young Investigator award for Atherosclerosis. Dr Penn is an active inventor and entrepreneur. He has generated intellectual property in the fields of diagnostics, biologics and devices. He is the founder and CSO/CMO of Juventas Therapeutics, Inc. (Cleveland, OH) and SironRx Inc. (Cleveland, OH), clinical stage regenerative medicine companies for cardiovascular disease and wound and bone healing, respectively. He is founder and CMO of Cleveland Heart Labs, Inc. (Cleveland, OH), a diagnostic company based on novel cardiovascular biomarkers. He was the PI of the Athersys MultiStem in AMI Phase I trial and serves on the Aastrom Biosciences Scientific Advisory Board. Dr Penn left the Cleveland Clinic in 2011 where he served as the Director of the Coronary Intensive Care Unit, Director of the Bakken Heart-Brain Institute and more recently Medical Director for Emerging Businesses and was named Innovator of the Year in 2006. He is recognized as one of the top 50 doctors in the history of the Cleveland Clinic (MedCity News, December 2011).